Liminatus Pharma (NASDAQ:LIMN) Stock Jumps 7.9% – Still a Buy?

Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) shares shot up 7.9% during mid-day trading on Friday. The company traded as high as $2.99 and last traded at $2.99. Approximately 13,582 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 32,036 shares. The stock had previously closed at $2.77.

Analyst Ratings Changes

Several research firms recently issued reports on LIMN. Wall Street Zen cut shares of Liminatus Pharma to a “strong sell” rating in a research report on Saturday, August 22nd. Weiss Ratings lowered shares of Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Analysis on Liminatus Pharma

Liminatus Pharma Stock Performance

The firm’s 50 day moving average is $3.36 and its two-hundred day moving average is $9.66. The stock has a market capitalization of $4.01 million, a PE ratio of -0.13 and a beta of 4.89.

Liminatus Pharma Company Profile

(Get Free Report)

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Featured Articles

Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.